Loading...

QNCX QUINCE THERAPEUTICS INC Expansion Plans 8-K Filing

QNC

QNCX

QUINCE THERAPEUTICS INC

(QNCX)

2025 8-K

Debt Settlement Completed

Delisting Warning

Financial Update

Board Resignations

Clinical Trial Results

Financial Results Update

Investor Day Update

Financial Agreement Update

Clinical Trials

Equity Offerings

Financial Statements

Financial Results

Compliance Regained

Financial Results

Financial Results

Annual Meeting Results

Appointment of Director

Bonus Information and Equit...

Amendment to Acquisition Fi...

Compliance regained with Na...

Termination of License Agre...

Appointment of COO

Acquisition and Guarantee A...

Departure of Chief Medical ...

Asset Acquisitions

Annual Meeting Results

Rights Agreement and Divide...

Departure of Director

Resignation and Appointment

Update on Development Pipel...

Asset Purchase Agreement

External Links:

On July 16, 2025, Quince Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 NEAT trial for its drug eDSP, involving 105 participants. This marks a significant step in their research for treating Ataxia-Telangiectasia.

AI Assistant

QUINCE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.